Arcturus Therapeutics Stock (NASDAQ: ARCT)

Arcturus Therapeutics

ARCTURUS THERAPEUTICS HOLDIN

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

10 Alarming Facts About FLiRT And LB.1, The New COVID Variants Reshaping The Pandemic

Biotech

Equities

Large Cap

News

Health Care

General

ARCT

CSLLY

CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer&#39;s Comirnaty in a Phase 3 study, persisting for one year and at a lower dose.

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer&#39;s Comirnaty Shot, Even At Lower Doses

Earnings

Price Target

Small Cap

Markets

Analyst Ratings

Trading Ideas

Arcturus Therapeutics (NASDAQ: ARCT) closed the last trading session at $21.10, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide.

Does Arcturus Therapeutics Have the Potential to Rally 216.35% as Wall Street Analysts Expect?

Earnings Beats

Penny Stocks

ANTX

FULC

ILMN

AN2 Therapeutics (NASDAQ: ANTX), a clinical-stage company, leverages its boron chemistry platform to develop novel small molecule therapeutics to potentially treat various infectious diseases and cancer indications.

AN2 Therapeutics Plunges 66% in a Month: Here&#39;s Why

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics Holdings Inc

ARCTIC STAR EXPL CORP by Arctic Star Exploration Corp.

Arctic Star Exploration Corp

Press Releases

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Abeona Therapeutics

Absci

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Annexon

Astria Therapeutics

Cidara Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Emergent BioSolutions

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Heron Therapeutics

IN8bio

Jade Biosciences

Neurogene

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Organogenesis Holdings

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Solid Biosciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Vigil Neuroscience

Verastem

XOMA Royalty

Scotiabank

Wells Fargo

Canaccord Genuity

HC Wainwright & Co.

BTIG

Comments

Arcturus Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell